Ameriprise Financial Inc. Purchases 315,608 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Ameriprise Financial Inc. increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 20.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,827,658 shares of the specialty pharmaceutical company's stock after acquiring an additional 315,608 shares during the period. Ameriprise Financial Inc. owned approximately 3.02% of Jazz Pharmaceuticals worth $225,076,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. LSV Asset Management lifted its holdings in Jazz Pharmaceuticals by 1.5% in the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after purchasing an additional 37,108 shares during the period. Pacer Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after acquiring an additional 115,102 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after buying an additional 320,724 shares in the last quarter. Capital World Investors lifted its holdings in Jazz Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock valued at $236,860,000 after acquiring an additional 104,195 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Jazz Pharmaceuticals by 4.8% during the fourth quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock valued at $195,506,000 after purchasing an additional 72,007 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Jazz Pharmaceuticals

In related news, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the transaction, the chief marketing officer now directly owns 82,024 shares of the company's stock, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 3,800 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,236 shares of company stock worth $3,956,190. Company insiders own 4.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on JAZZ. Barclays restated an "overweight" rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. HC Wainwright lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. StockNews.com downgraded Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. Finally, Royal Bank of Canada dropped their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research note on Wednesday. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $182.79.

Jazz Pharmaceuticals Trading Down 0.6 %

NASDAQ:JAZZ traded down $0.60 during trading hours on Friday, hitting $97.81. The stock had a trading volume of 1,217,193 shares, compared to its average volume of 833,461. The business's 50 day moving average is $118.96 and its 200-day moving average is $122.19. The company has a market cap of $6.03 billion, a price-to-earnings ratio of 13.78, a P/E/G ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same period in the prior year, the company earned $2.68 EPS. The firm's revenue was down .5% on a year-over-year basis. Sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.